ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1320

Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept

Paolo Semeraro1, Fabrizio Angeli1, Alessia Caproli1, Franco Franceschini2, Paolo Airò3 and Silvia Piantoni4, 1Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 4ASST Spedali Civili and University of Brescia, Brescia, Italy

Meeting: ACR Convergence 2023

Keywords: Biologicals, Biomarkers, immunology, rheumatoid arthritis, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1308–1344) RA – Treatments Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Helper T cells (Th) are key players in rheumatoid arthritis (RA). Th17 and Th17.1 have a prominent function in the early phase of inflammation, while Th1 characterize a well-established disease (Kotake S, 2017). Th22, characterized by synthesis of IL-22 (and IL-13 and TNF-α) but not IL-17A or IFN-γ, are still. In RA animal model, IL-22 hampered Th1 plasticity, favoring Th17 maintenance and survival (Justa S, 2014). Th9 are involved in RA synovitis, IL-9 being an enhancer of Th17 cells differentiation in the synovium (Chowdhury, 2018). Innate lymphoid cells (ILC) were recently described as critical in the perpetuation of immune responses during the autoimmune processes, being resident in the tissues and activating without the presence of antigen-specific cell receptors. The three major groups in the ILC family (1, 2, 3) mirror the canonical T helper subsets Th1, Th2, and Th17 (Wu X, 2020). Considering the crucial role played by the CD28 co-stimulation in the process of Th priming and its effect on inflammatory environment, we hypothesized that its blocker abatacept (ABA) might modulate the circulating levels of Th and ILC cells and their involvement in B-cell maturation and antigen-driven differentiation.

Methods: Sixteen bDMARDs-naïve RA patients [female/male=10/6; median (IQR) age=64 (54.3-67.6) years; disease duration=51 (30-108) months; 13/16 (81.3%) seropositive; C Reactive Protein (CRP)=6 (2.4-11.5) mg/L (normal value < 5 mg/L), CRP-28-joint Disease Activity Score (CRP-DAS28)=4 (3.3-4.4)] were enrolled before starting ABA. Peripheral blood mononuclear cells, obtained from the patients before the start of ABA therapy (T0) and after 12 months (T12), were extracellular stained and evaluated by flow cytometry (FACSCantoII, Beckton Dickinson). EULAR criteria were used to evaluate the treatment response [good and moderate responders (R), n=11 and non-responders (NR), n=5].

Results: Baseline CRP-DAS28 was differently correlated with various T helper cell subsets, but not with ILC (Table 1A). In the whole cohort, Th and ILC subpopulation levels did not significantly change between T0 and T12, except for Th22 levels (expressed as % of CD3+CD4+CCR6+CCR4+) which decreased [20.1 (17.93-23.53) vs 16 (14.1-19.4); p:0.016] (Table 1B), mainly in the R group [19 (17.75-20.5) vs 15.85 (13-17.45); p:0.004]. The same level of circulating subsets was found when comparing NR vs R patients at T0 and T12.

Conclusion: All the circulating Th cells expressing CCR6, which is the main chemokine receptor of Th17 and Th17-related cells, were positively correlated with the disease activity at baseline, except for Th22, a distinct Th lineage that can display plasticity towards Th1 and Th2 lineages under special circumstances, showing regulatory properties and participating to the early RA pathogenesis. The decrease of Th22 after CD28 blockade may suggest the potential role of ABA in targeting one of the earliest phases of the disease pathophysiology.

Supporting image 1


Disclosures: P. Semeraro: None; F. Angeli: None; A. Caproli: None; F. Franceschini: None; P. Airò: None; S. Piantoni: None.

To cite this abstract in AMA style:

Semeraro P, Angeli F, Caproli A, Franceschini F, Airò P, Piantoni S. Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-circulating-levels-of-helper-t-and-innate-lymphoid-cells-subsets-in-a-cohort-of-bdmards-naive-patients-with-rheumatoid-arthritis-treated-with-abatacept/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-circulating-levels-of-helper-t-and-innate-lymphoid-cells-subsets-in-a-cohort-of-bdmards-naive-patients-with-rheumatoid-arthritis-treated-with-abatacept/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology